This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US states say Sandoz must face antitrust claims in generic drugs case

( April 7, 2025, 20:56 GMT | Official Statement) -- MLex Summary: US states opposed Sandoz’s motion for summary judgment in a US case over generic drug pricing, saying it creates a straw-man version of the alleged overarching conspiracy that is different from what the states allege. Additionally, it mischaracterizes the record to argue that there is no evidence to support its straw man and its legal arguments have already been rejected by the court. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections